Figures & data
Table 1 Patient demographics and baseline characteristics by therapy type and age (safety set)
Figure 1 Number of patients in the vildagliptin and SU treatment cohorts with one or more HEs during Ramadan fasting according to (A) therapy type (monotherapy or dual therapy with metformin) and (B) age (<65 years or ≥65 years; primary analysis set).
Abbreviations: SU, sulfonylurea; HEs, hypoglycemic events.
![Figure 1 Number of patients in the vildagliptin and SU treatment cohorts with one or more HEs during Ramadan fasting according to (A) therapy type (monotherapy or dual therapy with metformin) and (B) age (<65 years or ≥65 years; primary analysis set).](/cms/asset/78ef1c27-6be2-4757-a501-c57c5692afcc/dmso_a_103692_f0001_b.jpg)
Figure 2 Mean (SD) change in HbA1c from prefasting baseline to study end for patients in vildagliptin and SU treatment cohorts.
Abbreviations: HbA1c, glycated hemoglobin; SU, sulfonylurea; SD, standard deviation.
![Figure 2 Mean (SD) change in HbA1c from prefasting baseline to study end for patients in vildagliptin and SU treatment cohorts.](/cms/asset/88d5dc55-082a-4381-a477-ed3b2b1962c5/dmso_a_103692_f0002_b.jpg)